A Phase II randomized, double-blind, placebo-controlled study of GBT440 to evaluate the safety, tolerability, pharmacokinetics and effect on hypoxemia in subjects with Idiopathic Pulmonary Fibrosis (IPF)
A study for patients with pulmonary fibrosis (PF) using study drug GBT440
Sponsor: Global Blood Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAQ8501
Contact: Tatiana Blue: 212-342-1518 / tjb2134@cumc.columbia.edu
Additional Study Information: The purpose of this study is to find out if subjects can take the prescribed dose of GBT440 without problems, and whether GBT440 is safe and helps subjects with IPF. GBT440 is called an investigational or experimental drug because it has not been approved for use in people by the Food and Drug Administration (FDA), the branch of U.S. government which approves new drugs, or by any other regulatory agency in other countries. Participation in this clinical trial will not have any effect on your disease management. Your disease management and treatment decisions will be determined by you and your health care professional.
This study is closed
David Lederer, MD
Do You Qualify?
Have you been diagnosed with Pulmonary Fibrosis? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Tatiana Blue